A pleural mesothelioma diagnosis is incredibly overwhelming for patients and caregivers. Knowing about treatment options can make it easier on these groups. One area of research is looking at blood-based biomarkers to test for mesothelioma. Two promising biomarkers are soluble mesothelin-related protein and cancer antigen 125. Both help monitor pleural[…]
Overall Survival
Multimodal Therapy Helps Improve Survival in Mesothelioma Patients
Malignant pleural mesothelioma is an aggressive cancer mainly caused by asbestos exposure. It is a cancer of the mesothelium, which is the lining of certain areas of the body including the lungs. The cancer is aggressive and hard to treat. There is hope though in new surgical and therapy methods.[…]
Immune Checkpoint Inhibitors Can Improve Survival in Mesothelioma Patients
Malignant pleural mesothelioma is a rare cancer that is hard to treat. There is a poor prognosis for people diagnosed with mesothelioma, but there is hope in the form of immune checkpoint inhibitors. There could be a chance of better outcomes in mesothelioma patients. A new article in Open Respiratory[…]
Surgery Improves Survival in Mesothelioma Patients
There is a debate about whether surgery for mesothelioma is beneficial. A new study was presented at the World Conference on Lung Cancer. The study looked at the survival of pleural mesothelioma patients who had different types of treatment. These included chemotherapy followed by surgery and chemotherapy only. The goal[…]
How the Immune System is Affected by Pleural Mesothelioma
A recent study looked at the body’s immune system and how it responds to pleural mesothelioma, a cancer of the lining of the lungs. Results were published in the journal Pathobiology. The immune cells around the tumor area of 60 pleural mesothelioma patients were studied. The researchers used biomarkers to[…]
ADI-PEG20 Improves Survival in Mesothelioma Patients
ADI-PEG20 is showing promising results for mesothelioma. It is the first treatment to be fully incorporated with chemotherapy in 20 years. The drug will bring hope to thousands of mesothelioma survivors and their families. The drug works by blocking a cancer’s food supply, preventing the spread of the cancer. It[…]
ADI-PEG 20 is Being Tested on Non-Epithelioid Mesothelioma
Polaris Group recently announced an application for a rolling submission of a new mesothelioma treatment. The Biologic License Application is the first step in becoming approved by the Food and Drug Administration. The treatment, known as ADI-PEG 20, is for the use on non-epithelioid mesothelioma patients alongside pemetrexed and platinum[…]
Pembrolizumab and Chemotherapy Improve Survival in Patients
Pleural mesothelioma, a cancer mainly caused by asbestos, is a hard cancer to treat. Diagnosis usually occurs when it is in a late stage, leading to limited treatment options. New clinical trials are always being performed to try to find a new treatment approach that could possibly extend the lives[…]
CIRT Radiation Therapy Beneficial for Lung Cancer Patients
Surgery is usually the first choice for patients and doctors for the treatment of early-stage cancer. There are other options though like radiotherapy. A special type of radiotherapy called Carbon-ion radiotherapy (CIRT)has become popular with doctors. A study in Japan showing how the therapy can benefit patients with early-stage lung[…]
Extended Pleurectomy and Decortication Surgery Worse than Just Receiving Chemotherapy
Extended pleurectomy decortication surgery combined with chemotherapy is associated with worse outcomes compared to just chemotherapy alone. Researchers looked at extended pleurectomy and decortication surgery alongside chemotherapy and found that there are worse survival outcomes, a higher chance of serious adverse events, and a diminished quality of life compared to[…]
